X
RARE icon

Xponance’s Ultragenyx Pharmaceutical RARE Stock Holding History

Xponance’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$345K Buy
16,466
+2,076
+14% +$46.7K ﹤0.01% 1194
2025
Q4 		$331K Buy
14,390
+896
+7% +$29.5K ﹤0.01% 1132
2025
Q3 		$406K Buy
13,494
+406
+3% +$12.2K ﹤0.01% 1041
2025
Q2 		$476K Buy
13,088
+536
+4% +$19.3K ﹤0.01% 973
2025
Q1 		$455K Buy
12,552
+347
+3% +$14.4K ﹤0.01% 965
2024
Q4 		$513K Buy
12,205
+940
+8% +$46.6K ﹤0.01% 942
2024
Q3 		$626K Buy
11,265
+174
+2% +$8.86K 0.01% 867
2024
Q2 		$456K Buy
11,091
+1,279
+13% +$54.6K ﹤0.01% 933
2024
Q1 		$458K Sell
9,812
-350
-3% -$16.5K ﹤0.01% 969
2023
Q4 		$486K Buy
10,162
+648
+7% +$25.1K 0.01% 937
2023
Q3 		$339K Buy
9,514
+53
+0.6% +$2.1K ﹤0.01% 1009
2023
Q2 		$436K Buy
9,461
+1,824
+24% +$84.6K 0.01% 946
2023
Q1 		$306K Sell
7,637
-78
-1% -$3.35K ﹤0.01% 1039
2022
Q4 		$357K Buy
7,715
+1,354
+21% +$53.3K 0.01% 997
2022
Q3 		$263K Sell
6,361
-85
-1% -$4.37K 0.01% 1027
2022
Q2 		$385K Buy
6,446
+750
+13% +$46.2K 0.01% 948
2022
Q1 		$414K Sell
5,696
-22
-0.4% -$1.53K 0.01% 956
2021
Q4 		$481K Buy
5,718
+97
+2% +$7.89K 0.01% 915
2021
Q3 		$507K Sell
5,621
-173
-3% -$15.6K 0.01% 884
2021
Q2 		$552K Buy
+5,794
New +$604K 0.01% 880
2021
Q1 		– Sell
-1,838
Closed -$254K – 1055
2020
Q4 		$254K Buy
+1,838
New +$218K 0.01% 995
2020
Q3 		– Sell
-2,627
Closed -$205K – 1047
2020
Q2 		$205K Buy
+2,627
New +$174K 0.01% 963

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Xponance's RARE Position: Q1 2026 in Review

Xponance increased its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, buying an estimated $46.7K and bringing the position to 16,466 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1194.

Xponance first reported a position in RARE in Q2 2020 and has held it in 22 quarters since. The position peaked at $626K in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Xponance held 16,466 shares of Ultragenyx Pharmaceutical worth $345K as of Q1 2026.
  • Xponance bought 2,076 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $46.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1194 holding.
  • Xponance first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and has held it in 22 quarters since.
  • Xponance's Ultragenyx Pharmaceutical position peaked at $626K in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.